Determination of MYD88 and CXCR4 mutation for clinical detection and their significance in Waldenstrom macroglobulinemia.

ABSTRACT:

Purpose

This study aims to explore the incidence and clinical features of MYD88 and CXCR4 mutations in patients with Waldenström macroglobulinemia (WM) and determine the optimal method for routine clinical practice. Additionally, we seek to evaluate the prognostic significance of these features across various therapeutic backgrounds [cytotoxic group, the Rituximab/Bortezomib-based group, and the Bruton's tyrosine kinase inhibitor (BTKi) group].

Experimental design

385 symptomatic WM patients were analyzed for MYD88 and CXCR4 mutations using Sanger sequencing, next-generation sequencing (NGS), allele-specific quantitative polymerase chain reaction (AS-PCR), and/or droplet digital PCR (ddPCR).

Results

The overall MYD88 mutation rate was 87.8%, relatively lower than that

SUBMITTER: Yan Y 

PROVIDER: S-EPMC11609624 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature